Methodological issues and new developments in the economic evaluation of vaccines

Expert Review of Vaccines

Volumn 2, Issue 5, 2003, Pages 649-660

  Beutels, Philippe ^a   Van Doorslaer, Eddy ^b   Van Damme, Pierre ^d   Hall, Jane ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^d NONE

Author keywords

Cost effectiveness; Immunization; Modeling

Indexed keywords

VACCINE;

ACCURACY; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE QUALITY; INFECTION; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; VACCINATION;

COMMUNICABLE DISEASE CONTROL; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; MODELS, ECONOMIC; VACCINES;

EID: 0142026120     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.5.649     Document Type: Review

References (45)

1. Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ. 1, 85-92 (1992).
2. Beutels P, Edmunds WJ, Antoñanzas F et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 20(1), 1-7 (2002). A consensus statement on many of the issues in this paper by a group of economists with considerable expertise on vaccination.
3. Beutels P. Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. University of Antwerp, Antwerp, Belgium (2002).
4. Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes: review of the literature. Pharmacoeconomics 21(1), 13-38 (2003).
5. Beutels P, Postma MJ. Economic evaluations of adult pneumococcal vaccination: a review of the literature. Expert Rev. Pharmacoeconomics Outcomes Res. 1(1), 47-58 (2001).
6. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ. 10(8), 751-774 (2001).
7. Postma MJ, Jansema P, van Genugten ML et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 62(7), 1013-1024 (2002).
8. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 37(1), 44-51 (2003).
9. McKie J, Richardson J. The rule of rescue. Soc. Sci. Med 56, 2407-2419 (2003).
10. Anderson RM, May RM. Infectious Diseases of Humans - Dynamics and Control. Oxford University Press, Oxford, UK (1991).
11. Daley DJ, Gani J. Epidemic modelling: an introduction. Cambridge University Press, Cambridge, UK (1999).
12. Keeling MJ, Grenfell BT. Disease extinction and community size: modeling the persistence of measles. Science 275(5296), 65-67 (1997).
13. Lieu TA, Cochi SL, Black SB et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271(5), 375-381 (1994).
14. Halloran ME, Watelet L, Struchiner CJ. Epidemiologic effects of vaccines with complex direct effect in an age structured population. Math. Biosci. 121(2), 193-225 (1994).
15. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18, 3263-3282 (1999).
16. Ray GT, Butler JC, Black SB, Shinefield HR et al. Observed costs and health care use of children in a randomized controlled trial of pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 21(5), 361-365 (2002).
17. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med 159(20), 2437-2442 (1999).
18. Wallinga J, Edmunds WJ, Kretzschmar M. Perspective: human contact patterns and the spread of airborne infectious diseases. Trends Microbiol. 7(9), 372-377 (1999).
19. Shkedy Z, Aerts M, Molenberghs G, Beutels P, Van Damme P. Modeling the force of infection using monotone local polynomials. Appl. Stat. (2003) (In Press).
20. van Boven M, de Melker HE, Schellekens JF, Kretzschmar M. Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. Math. Biosci. 164(2), 161-182 (2000).
21. Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Ann. Rev. Public Health 23, 115-134 (2002).
22. Dolan P. Utilitarianism and the measurement and aggregation of quality-adjusted life years. Health Care Anal. 9(1), 65-76 (2001).
23. Lieu TA, Black SB, Ray GT, Martin KE, Shinefield HR, Weniger BG. The hidden costs of infant vaccination. Vaccine 19(1), 33-41 (2000). Costing study illustrating that the intangible costs of vaccination may be substantial.
24. Olsen JA, Smith RD. Theory versus practice: a review of 'willingness-to-pay' in health and health care. Health Econ. 10(1), 39-52 (2001). An extensive review of willingness-to-pay studies in health care, it's theoretical basis vis-a-vis QALYs discussing to which extent practice corresponds with theory.
25. Smith RD. Construction of the contingent valuation market in health care: a critical assessment. Health Econ. 12(8), 609-628 (2003).
26. Hensher D. Stated preference analysis of travel choices: the state of practice. Transportation, 21, 107-133 (1994).
27. Ben-Akiva M, Boccara B. Discrete choice models with latent choice sets. Int. J. Res. Marketing 12, 9-24 (1995).
28. Adamowicz W, Louviere J, Williams M. Combining revealed and stated preference methods for valuing environmental amenities. J. Environ. Manage. Econ. 26, 271-292 (1994).
29. Viney R, Lancsar E, Louviere J. Discrete choice experiments to measure consumer preferences for health and healthcare. Expert Rev. Pharmacoeconomics Outcomes Res. 2(4), 319-326 (2002).
30. Louviere JJ, Hensher DA, Swait JD. Stated Choice Methods: analysis and applications. Cambridge University Press, Cambridge UK (2000).
31. Swait J, Louviere J. The role of the scale parameter in the estimation of estimation and comparison of multinomial logit models. J. Marketing Res. 30, 305-314 (1993).
32. Hall J, Kenny P, King M et al. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination. Health Econ. 11, 457-465 (2002). The only application of discrete choice event modelling in the field of vaccination.
33. Hall AJ, Robertson RL Crivelli PE et al. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans. R. Soc. Trop. Med Hyg. 87, 333-336 (1993).
34. Edmunds WJ, Dejene A, Mekonnen Y, Haile M et al. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plann. 15(4), 408-416 (2000).
35. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18(5-6), 407-415 (1999).
36. Beutels P, Van Damme P, Van Casteren V, Gay N et al. The difficult quest for data on 'vanishing' vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 20(29-30), 3551-3559 (2002).
37. Beutels Ph, Gay NJ. Economic evaluation of options for measles vaccination strategy in a hypothetical western European country. Epidemiol. Infect. 130(2), 273-283 (2003). A recent example of the use of a dynamc epidemiological model for cost-effectiveness and cost-benefit analysis.
38. Weniger BG, Chen RT, Jacobson SH, Sewell EC et al. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. Vaccine 16(19), 1885-1897 (1998).
39. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russel LB, Weinstein MC (Eds). Oxford University Press, NY, USA 176-213 (1996).
40. Beutels Ph, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children, J. Infect. Dis. 174(Suppl. 3), S335-341 (1996).
41. Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In: Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russel LB, Weinstein MC (Eds). Oxford University Press, NY, USA 25-53 (1996).
42. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278(16), 1333-1339 (1997).
43. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 16(1), 33-64 (1997).
44. Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med. Care 38(6), 679-685 (2000).
45. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd immunity. Med. Decis. Making 23(1), 76-82 (2003). A well-organized overview outlining the various issues of dynamic versus static modelling, with illustrations on cost-effectiveness impact